Anaplastic Astrocytoma: Clinical Trials

122 trials for Anaplastic Astrocytoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

62 completed, 23 terminated, 11 recruiting, 9 active not recruiting. 60 Phase 1, 44 Phase 2, 10 Phase 3, 4 Not applicable, 2 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 160Completed 43, Terminated 6, Recruiting 5, Active not recruiting 3, Withdrawn 2, Suspended 1
Phase 244Completed 19, Terminated 11, Recruiting 7, Active not recruiting 4, Suspended 1, Unknown 1, Withdrawn 1
Phase 310Unknown 4, Completed 3, Terminated 2, Withdrawn 1
Not applicable4Unknown 2, Terminated 1, Withdrawn 1
Early Phase 12Completed 1, Recruiting 1
Phase 41Active not recruiting 1

Follow Anaplastic Astrocytoma: new trials by email Literature Review of Anaplastic Astrocytoma trials Research Report on Anaplastic Astrocytoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
Bevacizumab-Containing Regimens, Non-Bevacizumab Regimens, BRAF ± MEK Targeted Therapy - Recurrent Malignant Glioma, Glioblastoma
Active not recruitingBlokhin's Russian Cancer Research Center10002026-02-012026-03-04
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2 - High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Early Phase 1RecruitingNationwide Children's Hospital152025-08-032026-06-29
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
SIACI of cetuximab and bevacizumab - Glioblastoma Multiforme, Anaplastic Astrocytoma
Phase 1 / Phase 2RecruitingUniversity of Miami202025-06-192025-12-08
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Ribociclib, Everolimus, Temozolomide (TMZ) - High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Phase 2RecruitingNationwide Children's Hospital1202024-08-222026-05-29
Targeted Pediatric High-Grade Glioma Therapy
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
RecruitingNationwide Children's Hospital3502024-08-022026-09-08
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
DB107-RRV, DB107-FC - High Grade Glioma, Anaplastic Astrocytoma
Phase 2RecruitingAshish Shah332024-05-012026-05-28
Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas
PSMA PET-CT - Glioma, Astrocytoma
Not applicableUnknownAll India Institute of Medical Sciences, Bhubaneswar352024-02-012024-02-08
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
Glioblastoma, Anaplastic Astrocytoma
Active not recruitingColumbia University202024-01-302026-08-19
Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
Anaplastic Astrocytoma, Diffuse Brainstem Glioma
TerminatedPediatric Brain Tumor Consortium572023-07-122026-04-23
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
PCI 24781, Temozolomide - Recurrent High Grade Glioma, Anaplastic Astrocytoma
Phase 1RecruitingUniversity of Nebraska242023-06-262026-09-14
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years - Medulloblastoma, Glioblastoma Multiforme
Phase 1Active not recruitingChildren's Oncology Group352022-07-012026-06-02
Study of Pembrolizumab and M032 (NSC 733972)
M032, Pembrolizumab - Glioblastoma Multiforme, Anaplastic Astrocytoma
Phase 1 / Phase 2RecruitingUniversity of Alabama at Birmingham282022-02-252026-01-22
Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
OS2966, Gadoteridol - Glioma, Malignant, High Grade Glioma
Phase 1TerminatedOncoSynergy, Inc.72021-03-022023-08-18
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
ONC206 - Central Nervous System Neoplasms, Glioblastoma
Phase 1Active not recruitingJazz Pharmaceuticals352020-10-262026-11-09
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
INCB7839 - Glioblastoma Multiforme, Anaplastic Astrocytoma
Phase 1CompletedPediatric Brain Tumor Consortium132020-07-272026-10-01
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture - Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified
Phase 2Active not recruitingNational Cancer Institute (NCI)582020-02-202026-11-12
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
Extended Release Flucytosine, NovoTTF-100A Device, Quality-of-Life Assessment - Anaplastic Astrocytoma, Glioblastoma
Phase 2 / Phase 3WithdrawnNRG Oncology2020-01-312026-05-07
Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg - High Grade Glioma, Anaplastic Astrocytoma
Phase 1TerminatedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins72019-12-062023-10-06
Pediatric Long-Term Follow-up and Rollover Study
dabrafenib, trametinib - Diffuse Astrocytoma, Anaplastic Astrocytoma
Phase 4Active not recruitingNovartis Pharmaceuticals1632019-11-042026-08-27
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
Encorafenib, Binimetinib, Research Bloods - High Grade Glioma, BRAF V600E
Phase 2TerminatedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins52019-07-292024-10-31

Showing 20 of 122. Sign in to see all of them.

Narrower conditions

Astrocytoma (122)  ·  Glioblastoma (113)  ·  Glioma (79)  ·  Oligodendroglioma (55)  ·  Brain Neoplasms (46)  ·  Gliosarcoma (32)  ·  Diffuse Intrinsic Pontine Glioma (14)  ·  Ependymoma (12)  ·  Neoplasms (12)  ·  Medulloblastoma (9)  ·  Recurrence (7)  ·  Central Nervous System Neoplasms (6)  ·  Neuroectodermal Tumors, Primitive (6)  ·  Meningioma (5)  ·  Neoplasms, Neuroepithelial (4)

Broader conditions

Neoplasms by Histologic Type (122)  ·  Neoplasms, Glandular and Epithelial (122)  ·  Neoplasms, Nerve Tissue (122)  ·  Neuroectodermal Tumors (121)  ·  Neoplasms, Germ Cell and Embryonal (120)  ·  Neoplasms, Neuroepithelial (118)  ·  Neoplasms (110)  ·  Neoplasms by Site (67)  ·  Nervous System Diseases (66)  ·  Nervous System Neoplasms (66)  ·  Central Nervous System Diseases (62)  ·  Brain Diseases (61)  ·  Central Nervous System Neoplasms (59)  ·  Glioma (43)  ·  Infratentorial Neoplasms (16)

Interventions

Temozolomide (20)  ·  Bevacizumab (9)  ·  Radiotherapy (9)  ·  Surgical Procedures, Operative (6)  ·  Flucytosine (5)  ·  IL13-PE38 (5)  ·  Lomustine (5)  ·  Radiation (5)  ·  Carboplatin (4)  ·  Carmustine (4)  ·  Magnetic Resonance Spectroscopy (4)  ·  Radiotherapy, Intensity-Modulated (4)  ·  trametinib (4)  ·  vocimagene amiretrorepvec (4)  ·  Cetuximab (3)

Sponsors

National Cancer Institute (NCI) (12)  ·  Northwell Health (7)  ·  INSYS Therapeutics Inc (5)  ·  Pediatric Brain Tumor Consortium (4)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4)  ·  Tocagen Inc. (4)  ·  Children's Oncology Group (3)  ·  Nationwide Children's Hospital (3)  ·  Candel Therapeutics, Inc. (2)  ·  Isarna Therapeutics GmbH (2)  ·  Jonsson Comprehensive Cancer Center (2)  ·  NRG Oncology (2)  ·  Novartis Pharmaceuticals (2)  ·  Roswell Park Cancer Institute (2)  ·  Shandong Lanjin Pharmaceuticals Co.,Ltd (2)

Countries

United States (100)  ·  Canada (13)  ·  Germany (12)  ·  Australia (7)  ·  France (6)  ·  Netherlands (6)  ·  United Kingdom (6)  ·  Israel (5)  ·  Russia (5)  ·  China (4)  ·  Italy (4)  ·  New Zealand (4)  ·  Argentina (3)  ·  Belgium (3)  ·  Brazil (3)

Top investigators

John Boockvar, MD (5)  ·  Asha Das, MD (3)  ·  Katherine E Warren, M.D. (3)  ·  Maryam Fouladi, MD (3)  ·  Annick Desjardins, MD (2)  ·  E. Antonio Chiocca, MD, PhD (2)  ·  Margot Lazow, MD (2)  ·  Stuart A Grossman, MD (2)  ·  Alexandra Miller, MD, PhD (1)  ·  Amy L Bredlau, MD (1)  ·  Andrew B. Lassman, MD (1)  ·  Andrew Cluster, M.D. (1)  ·  Arti B Gaur, PhD (1)  ·  Ashish Shah, MD (1)

Results publications

PMID 34331515, PMID 12749708, PMID 15809479, PMID 16877732, PMID 17429084, PMID 20725730, PMID 21242491, PMID 21844505, PMID 22578793, PMID 24786603, PMID 25098701, PMID 25338318, PMID 26843484, PMID 26860632, PMID 27252174, PMID 27370396, PMID 28690586, PMID 29762717, PMID 30151703, PMID 31795071, PMID 32009149, PMID 32064499, PMID 32285998, PMID 33119048, PMID 33571520, PMID 33838625, PMID 34142085, PMID 34214495, PMID 34359048, PMID 34943910, PMID 35417530, PMID 36006068, PMID 36705923, PMID 37004712, PMID 37610803, PMID 37643378, PMID 37733309, PMID 37790490, PMID 38182653, PMID 38215438, PMID 38216554, PMID 38719809, PMID 39560182, PMID 40132910, PMID 40225909, PMID 41325560, PMID 41740060, PMID 9390198

NIH funding

UM1CA081457 (4), U01CA081457 (3), U10CA180886 (3), UM1CA137443 (3), 2015 (2), P30CA016056 (2), U10CA098543 (2), U10CA180868 (2), UM1CA097452 (2), 2023 (1), P30CA015083 (1), P30CA036727 (1), P50CA108961 (1), P50CA221747 (1), R01CA125244 (1)